What is the appropriate next step in management for a patient with markedly elevated fecal calprotectin and fecal neutrophils, but negative Clostridioides difficile PCR, normal stool culture, no ova/parasites, and negative Helicobacter pylori stool antigen?

Management of Markedly Elevated Fecal Calprotectin with Negative Infectious Workup

This patient requires endoscopic evaluation (colonoscopy with ileoscopy and biopsies) to assess for inflammatory bowel disease (IBD), as the markedly elevated fecal calprotectin (1589.1 µg/g) with fecal neutrophils strongly suggests active intestinal inflammation after excluding infectious etiologies.

Clinical Context and Interpretation

The laboratory findings reveal:

• Fecal calprotectin of 1589.1 µg/g - nearly 10-fold above the upper limit of normal (>160 µg/g is considered elevated) 1
• Fecal neutrophils present - indicating active intestinal inflammation 2
• Negative infectious workup - C. difficile PCR negative, no enteric pathogens, no ova/parasites, negative H. pylori 1, 3

This constellation strongly suggests inflammatory bowel disease (Crohn's disease or ulcerative colitis) as the underlying diagnosis 4.

Rationale for Endoscopic Assessment

Why Endoscopy is Mandatory

Fecal calprotectin >150 mg/g in symptomatic patients warrants endoscopic evaluation rather than empiric treatment, according to AGA guidelines 1, 3. This recommendation is even more compelling when:

• The calprotectin level is extremely elevated (>1500 µg/g suggests severe mucosal inflammation) 4, 2
• Fecal neutrophils are present, confirming active neutrophilic inflammation 2
• This appears to be a new presentation requiring definitive diagnosis 3

What Endoscopy Will Accomplish

The endoscopic evaluation should include:

• Colonoscopy with terminal ileum intubation to assess for ulcerative colitis vs. Crohn's disease 1
• Multiple biopsies from affected and unaffected areas for histologic confirmation 3
• Assessment of disease extent and severity to guide treatment decisions 3
• Exclusion of cytomegalovirus colitis (which biomarkers cannot detect) 3

Important Considerations Before Endoscopy

Confirm Infectious Causes Are Truly Excluded

While the workup appears comprehensive, ensure:

• C. difficile testing was performed appropriately - the negative PCR effectively rules out CDI 1, 5, 6
• Consider that fecal calprotectin can be elevated in C. difficile infection, but levels >1500 µg/g are more typical of IBD 5, 6
• The negative stool culture excludes common bacterial pathogens 1, 3

Clinical Symptom Assessment

Determine the patient's symptom severity to guide urgency:

• Moderate to severe symptoms (frequent bloody diarrhea, significant stool frequency increase) - the elevated calprotectin >150 mg/g can "rule in" active inflammation and endoscopy should be performed promptly 3
• Mild symptoms - endoscopic assessment is still recommended over empiric treatment when biomarkers are this elevated 3

Common Pitfalls to Avoid

Do Not Empirically Treat Without Tissue Diagnosis

Avoid starting immunosuppressive therapy before obtaining histologic confirmation 3. The AGA explicitly recommends against empiric treatment adjustment when:

• Biomarkers are elevated but diagnosis is uncertain 1
• This appears to be a new diagnosis requiring definitive characterization 3

Do Not Repeat Calprotectin Instead of Proceeding to Endoscopy

While repeat biomarker testing in 3-6 months may be reasonable in patients with borderline elevations or established IBD in remission 3, this strategy is inappropriate here because:

• The calprotectin is extremely elevated (not borderline) 4
• The patient lacks an established IBD diagnosis 1
• Delaying diagnosis risks disease progression and complications 1

Recognize Calprotectin Assay Limitations

The lab report correctly notes that BUHLMANN fCAL test results cannot be used interchangeably with other assays 3. This is important for:

• Future monitoring (use the same assay) 3
• Interpreting cutoff values (which may vary between assays) 3

Post-Endoscopy Management Algorithm

Once endoscopy establishes the diagnosis:

If IBD is confirmed:

• Initiate appropriate therapy based on disease severity and extent 1
• Use fecal calprotectin <150 mg/g as a treatment target to monitor response 1, 3
• Repeat endoscopy 6-12 months after treatment initiation to confirm mucosal healing 1

If endoscopy is normal or shows minimal inflammation:

• Consider other causes of elevated calprotectin (though levels >1500 µg/g are rarely seen outside IBD) 4
• Reassess for missed infectious etiologies 1, 3
• Consider small bowel imaging if Crohn's disease is suspected but colonoscopy is unrevealing 1